ECRONICON OPEN ACCESS

EC PHARMACOLOGY AND TOXICOLOGY
Review Article

Design Strategies for the Safe Utilisation of Reactive Oxygen Species in Nanomedicine

Mittal Vasava, Rathodiya Mehul, Makwana Devanshu and Mihir Y Parmar*

Department of Pharmacology, Krishna School of Pharmacy, Drs. Kiran and Pallavi Patel Global University, Krishna Edu Campus, Varnama, Vadodara, Gujarat, India

***Corresponding Author:** Mihir Y Parmar, HOD and Professor, Department of Pharmacology, Krishna School of Pharmacy, Drs. Kiran and Pallavi Patel Global University, Krishna Edu Campus, Varnama, Vadodara, Gujarat, India.

Received: April 12, 2026; **Published:** May 01, 2026

Abstract

Reactive oxygen species (ROS) provide powerful therapeutic opportunities in Nano medicine, enabling tumour-selective oxidative removal, redox-responsive drug release, and antioxidant protection in inflammatory and neurodegenerative disorders. Particular attention is given to thorough ROS quantification, cross validation, bio distribution designing, and adherence to international regulatory standards to ensure reproducibility and clinical translation. However, their high reactivity also introduces risks of off-target cytotoxicity, immunological disturbance, and long-term nanoparticle accumulation. Protective strategies-including antioxidant co-delivery, incorporation of self-limiting catalytic (precaution) and the use of biodegradable or renal passable confirmation-are highlighted as key to reducing systemic toxicity. This review proposes a comprehensive safety-by-design framework for ROS-modulating nanoplatforms, focusing on selective ROS species deployment, spatiotemporal activation using endogenous or exogenous triggers, and precise catalytic regulation to prevent uncontrolled oxidative stress. Emerging modalities such as photodynamic, chemo dynamic, sono dynamic, and nano enzyme systems are critically evaluated confirm ROS-scavenging and redox-responsive nano carriers.

Keywords: *Reactive Oxygen Species (ROS); Nanomedicine; Safety-By-Design; Photodynamic Therapy (PDT); Chemodynamic Therapy (CDT); Sonodynamic Therapy (SDT); Nanozymes; Antioxidant Nanocarriers; Redox-Responsive Polymers; Spatiotemporal Activation;*

Introduction

Introduction to the safe deployment of ROS in nanotherapeutics

Reactive oxygen species (ROS)-including superoxide anion ($O_2\bullet^-$), hydrogen peroxide (H_2O_2), hydroxyl radical (•OH), and singlet oxygen ($^1O_2$)-exert a bifunctional influence within biological systems, serving as both indispensable signalling intermediates and pathological mediators of oxidative injury [1]. The therapeutic promise of ROS-centric nanomedicine is counterbalanced by critical safety considerations-namely, inadvertent off-target oxidative cytotoxicity, immunostimulation or suppression, nanoparticulate bioaccumulation, and ambiguous elimination kinetics Recent advances in ROS-generating nanomedical architectures have sought to exploit this paradox, engendering controlled oxidative bursts to ablate malignant cells, or conversely, harnessing antioxidant nanozymes to attenuate oxidative stress in conditions such as cerebral ischaemia, chronic inflammation, and neurodegenerative disorders [2,11,14]. This treatise delineates a comprehensive design framework for engineering ROS-modulating nanotherapeutics that harmonise efficacy with biosafety [2,3,9], integrating principles of selective ROS species deployment, spatiotemporal activation, controlled catalytic kinetics, biodegradability, and

adherence to rigorous ROS quantification protocols derived from international consensus guidelines and contemporary scholarly reviews [1,5]. At homeostatic concentrations, ROS orchestrate intricate intracellular signalling cascades; in surfeit, they precipitate deleterious oxidative perturbations to biomacromolecules [8].



Figure 1

Foundational safety paradigms for ROS-Modulating nanocarriers

Discriminative selection of ROS species to optimise therapeutic index

Distinct ROS moieties exhibit divergent physicochemical reactivities, diffusional capacities, and cellular penetrance [1]. Hydroxyl radicals (•OH), while exceptionally reactive, are non-selective and confer substantial collateral damage risk. Hydrogen peroxide, by contrast, possesses greater diffusibility and facilitates modulatory effects upon redox-sensitive signalling pathways [3]. A safety-oriented nanocarrier strategy entails judicious selection of ROS type congruent with pathological context-deploying high-reactivity, short-range ROS for localised tumouricidal action, or employing selective scavenging strategies for neuroprotective or anti-inflammatory interventions [2,8]. Singlet oxygen ($^1O_2$), exploited in photodynamic therapy (PDT), benefits from a limited spatial propagation radius, thus conferring intrinsic localisation [6].

Spatiotemporally triggered ROS generation

Inducible ROS production constitutes a cardinal safety measure [3]. Nanoplatform activation may be orchestrated via: Orthogonal dual-trigger designs: Converging targeting ligands with microenvironment-sensitive modules to confine ROS bursts exclusively to diseased loci, thereby optimising therapeutic window and minimising iatrogenic oxidative insult [2,6]. Endogenous biochemical cues: Pathological hallmarks such as acidic microenvironment, aberrantly elevated enzymes, or heightened H_2O_2 levels. Exogenous stimuli: Photonic irradiation (PDT), acoustic activation (sonodynamic therapy), or ionising radiation, affording sub-millimetre precision in ROS release [4].

Regulation of ROS kinetics via catalytic modulation

Modulating catalytic loading density and nanoparticle surface topology [3]. Catalytic nanotherapeutics, encompassing Fenton or Fenton-like chemodynamic therapy (CDT) and nanozymatic catalysis, necessitate scrupulous kinetic control to forestall ROS overproduction

[1,4]. Strategies include: Modulating catalytic loading density and nanoparticle surface topology [3]. Incorporating catalytic "failsafe" moieties that auto-inhibit when ROS thresholds are exceeded [4]. Engineering self-limiting reaction schemes contingent upon substrate depletion [2].

Co-delivery of antioxidants and protective countermeasures

Additionally, "redox-off switches" can be embedded to automatically transition the nanoplatform from pro-oxidant to antioxidant mode once ROS concentrations surpass safe operational parameters [3]. To mitigate off-target oxidative sequelae, co-localisation of antioxidants-either molecular scavengers or enzymatic mimetics (SOD, catalase)-within ROS-active nanodomains is recommended [5].

Biodegradability and clearance as imperatives of safety

For inherently non-degradable constructs (e.g. cerium oxide), longitudinal biodistribution and chronic toxicity surveillance are indispensable [7,17]. Long-term persistence of nanomaterials presents chronic oxidative and immunological hazards [7,16]. Employing biodegradable matrices-such as polyesters, iron oxide scaffolds, or ultrasmall architectures facilitating renal clearance-remains paramount [2].



Figure 2

Engineering nanoplatforms for controlled ROS modulation

ROS-generating modalities

- Photodynamic therapy (PDT): Photosensitiser-loaded nanocarriers enable spatially circumscribed ROS induction under precise photonic exposure [1,4].
- Chemodynamic therapy (CDT): Fenton-active nanomaterials yield hydroxyl radicals in acidic tumoural milieus. Safety modulation includes catalytic passivation and reaction confinement via pH-specific activation [1,5].
- Sonodynamic and radiodynamic approaches: Acoustic or ionising energy permits deeper tissue penetration. Protective measures require calibrated energy dosimetry, non-target shielding, and ancillary antioxidant deployment [6]. Hypoxic tumours may benefit from auxiliary oxygen-generating modules (e.g. catalase-mimicking cores) to circumvent hypoxia-mediated ROS suppression [3].
- Nanozymatic catalysis: Peroxidase- or oxidase-mimetic nanostructures amplify ROS production but require activity restriction through substrate availability and surface passivation [3,4].

ROS-scavenging and antioxidant nanoplatforms

- ROS-responsive polymeric systems: Thioketal and boronate-containing carriers undergo structural disassembly upon ROS exposure, releasing therapeutic payloads while generating benign degradation products [5,10].
- Intrinsic antioxidant nanomaterials: Cerium oxide, Prussian Blue, and manganese oxide demonstrate SOD- and catalase-like activities [3,7]. Over-scavenging must be avoided to preserve physiological redox homeostasis [2].



Figure 3

Triggering modalities and microenvironmental concordance

Physical activation

- Ionising radiation: Augments nanoparticle-mediated ROS yields but necessitates balancing synergistic oxidative stress against radiotoxicity [6].
- Light-based (PDT): Localised photonic irradiation demands meticulous dosimetric calibration [4].
- Ultrasound (SDT): Facilitates penetration to deeper tissue strata; potential adverse cavitation must be minimised [6].

Chemical and biochemical activation

- pH-sensitive designs: Inert at physiological pH, activated in pathological acidosis-avoiding activation in benign acidic niches.
- Enzyme-responsive coatings: Matrix metalloproteinase (MMP)-triggered release ensures disease-specific ROS induction [5,6].
- ROS-autoregulated activation: Constructs capable of dynamic transition from pro-oxidant to antioxidant state upon threshold detection.



Figure 4

ROS quantification and regulatory compliance

Avoidance of over-reliance on DCFH-DA fluorescence due to specificity limitations [3]. Consensus recommendations mandate: Use of complementary ROS assays with enzymatic control verification [1,3]. Contextual reporting of assay parameters (oxygenation, serum composition, illumination fluence) [1,4]. *In vivo* biodistribution mapping, oxidative biomarker profiling, and histopathological confirmation [7]. Full transparency for reproducibility and regulatory audit [1,2].

Figure 5

Preclinical safety assessment

Organ-specific surveillance for oxidative histopathology in liver, spleen, kidneys, lungs, and brain [7,12]. Biomarker-guided dose optimisation using indices such as H_2O_2 concentration and protein carbonylation [2,5]. Immunological profiling encompassing cytokine networks and complement activation [3,7].



Figure 6

Exemplar safety-by-design implementations

MnO_2 nanozymes in ischaemia-reperfusion: Catalase-like systems that exhibit activity attenuation under physiological redox states, averting interference with normal signalling [11]. Multimodal PDT nanoconstructs: Layered architectures combining photosensitisers, oxygenation modules, pathology-specific triggers, and ROS attenuation safeguards [4,6].

Translational and regulatory considerations

Comprehensive physicochemical characterisation including trace contaminant profiling [16]. Definitive mechanistic evidence of site-specific ROS induction with negligible systemic spillover [4]. Longitudinal pharmacokinetic and toxicological datasets for non-degradable systems [7]. Conformance to internationally ratified ROS measurement standards [3].

Emerging safety innovations

- Redox biomarker-driven patient stratification: Personalises ROS-based interventions for optimised safety margins.
- Mitochondriotropic ROS modulation: Enhances tumour selectivity yet necessitates metabolic safety verification.
- Dynamic ROS-responsive nanomaterials: Capable of bidirectional modulation between ROS generation and scavenging.
- Advanced *in vivo* ROS imaging: Enables precise spatiotemporal mapping of oxidative events.

For these emerging topics, citation support may come from a combination of foundational and future-state reviews, such as [13-15].

Safety assurance checklist

1. Characterize the nanoparticle fully: Size, zeta potential, composition, metal content, stability in serum, release profile, and catalytic rates (kcat or turnover where relevant).
2. Quantify ROS species specifically (don't rely on a single probe): Use orthogonal assays for ·OH, singlet oxygen, H_2O_2 and superoxide; follow published SOPs for DCFH-DA and other probes.
3. Include appropriate biological controls: Antioxidant pre-treatment, catalase/SOD addition, and ROS scavengers to prove mechanism.

Conclusion

- Test in physiologically relevant oxygen/pH: Hypoxic chambers, serum-supplemented media, and 3D models or organoids when possible.
- Biodistribution and clearance: Quantify accumulation in liver/spleen/kidney and persistence over time (ICP-MS for metals). Assess oxidative damage markers in major organs (lipid peroxidation, protein carbonyls, DNA oxidation).
- Immunotoxicity and inflammation panels: Cytokines, complement activation, and histopathology for oxidative injury.
- Long-term studies for persistent nanomaterials: Repeat-dose toxicity and reproductive/neurotoxicity where relevant.

Bibliography

1. Yang B., *et al*. "Reactive oxygen species (ROS)-based nanomedicine". *Chemical Reviews* 119.8 (2019): 4881-4985.
2. Liu J., *et al*. "Biomedical application of ROS-responsive nanocarriers in cancer, inflammation, and neurodegenerative diseases". *Frontiers in Chemistry* 8 (2020): 838.
3. Chenyang Zhang., *et al*. "Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment". *Advanced Science* 8.3 (2020): 2002797.

4. Jinyong Lin., *et al*. "A review on reactive oxygen species-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy". *Nanoscale* 15.28 (2023): 11813-11833.

5. Singh P., *et al*. "Nanoformulation-based medicines for the treatment of reactive oxygen species-induced diseases: a review". *Nanofabrication* 10 (2025).

6. Li Z., *et al*. "Reactive oxygen species-dependent nanomedicine therapeutic modalities for gastric cancer". *Nanoscale Advances* 7.11 (2025): 3210-3227.

7. Fadeel B and Garcia-Bennett AE. "Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications". *Advanced Drug Delivery Reviews* 62.3 (2010): 362-374.

8. Samrot AV., *et al*. "Nanoparticles, a double-edged sword with oxidant as well as antioxidant properties-a review". *Oxygen* 2.4 (2022): 591-604.

9. Kamaly N., *et al*. "Nanomedicine in the ROS-mediated pathophysiology: applications and clinical advances". *Nanomedicine* 11.8 (2015): 2033-2040.

10. Yukio Nagasaki. "Design and application of redox polymers for nanomedicine". *Polymer Journal* 50.2 (2018): 821-836.

11. Adityanarayan Mohapatra and In-Kyu Park. "Recent advances in ROS-scavenging metallic nanozymes for anti-inflammatory diseases: a review". *Chonnam Medical Journal* 59.1 (2023): 13-23.

12. Balasubramanyam A., *et al*. "Review on metal-based nanoparticles: role of reactive oxygen species in renal toxicity". *Chemical Research in Toxicology* 33.10 (2020): 2503-2514.

13. Li Z., *et al*. "Reactive oxygen species-dependent nanomedicine therapeutic modalities for gastric cancer". *Nanoscale Advances* 7.11 (2025): 3210-3227.

14. Popat Mohite., *et al*. "Bioactive compound-fortified nanomedicine in the modulation of reactive oxygen species and enhancement of the wound healing process: a review". *Pharmaceutics* 17.7 (2025): 855.

15. Oberdörster G., *et al*. "Nanomaterials and nanoparticles: sources and toxicity". *Environmental Health Perspectives* 114.10 (2008): 823-832.

16. Megan S Lord., *et al*. "Redox active cerium oxide nanoparticles: current status and burning issues". *Small* 17.51 (2021): e2102342.

17. Yukio Nagasaki. "Design and application of redox polymers for nanomedicine". *Polymer Journal* 50.2 (2018): 821-836.

Volume 14 Issue 5 May 2026